10x Genomics, Inc.
10x Genomics, Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Pleasanton, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $643 million and a loss of $44 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.3 out of ten, 9 of 9 metrics filed: past 6.0 out of ten, present 6.5 out of ten, future 6.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2019. 80th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.5 out of ten. +23.5% a year over 8 filed years; profitable in 0 of 8. 65th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 2.0 out of ten. Share count grew 3.1% a year. 0% of cash flow returned. Insiders: 50 sales, 0 purchases. 20th percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 6.3 out of ten. ROE -5%: lost 5¢ per shareholder dollar. Leverage 24%: owes 24¢ per asset dollar. 63rd percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 6.4 out of ten. top 36% of 21 in its family; net margin -6.8%. 64th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 7.1 out of ten. top 29% of 21 in its family for leadership; chief executive since 2019. 71st percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 8.8 out of ten. top 12% of 21 in its family for room to expand. 88th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 2.9 out of ten. bottom 29% of 21 in its family for growth drivers. 29th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.4 out of ten. top 36% of 20 in its family for expectations against reality. 64th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-13 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-07 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-10-07. Filings on record since 2019. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Single Cell Consumables 56%, Spatial Consumables 22%, Licensing and Royalty Revenue 7%, Spatial Instruments 5%, Service 5%, Single Cell Instruments 4%. By geography: United States 54%, Europe, Middle East and Africa 25%, China 11%, Asia-Pacific (excluding China) 8%, Americas (excluding United States) 2%. As tagged in its annual report (Form 10-K, filed 2026-02-13).
Who runs it
Saxonov, Serge (Chief Executive Officer); Hindson, Benjamin J. (Title: President and Chief Scientific Officer); Taich, Adam (Chief Financial Officer); Suliman, Shehnaaz (director); Stuelpnagel, John R (director); Teichmann, Sarah A. (director); Kosaraju, Sridhar (director); Mateo, Alan (director); Popovits, Kimberly J (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.